Latest News

Bernstein Liebhard LLP reports on a February 28, 2012 health directive issued by the British Medical Journal and the British Broadcasting Corporation. A joint investigation conducted by the two entities resulted in an updated warning, affecting thousands of individuals who received metal-on-metal hi...

Bernstein Liebhard LLP reports that on February 27, 2012, a jury trial began in the Superior Court for Atlantic County, New Jersey in In re: Fosamax Litigation (No. 282 N.J. Super Ct.). Flores v. Merck and Sessner v. Merck, which are both part of the consolidated state court litigation and are being...

Fosamax-related litigation is moving forward in both federal and state courts. The latest Fosamax lawsuit news occurred on February 27, 2012 when the sixth Fosamax trial began in the Superior Court for Atlantic County, New Jersey. The two cases, which are being tried together, are Flores v. Merck an...

On February 4, 2012, The Sunday Telegraph reported on the link between metal-on-metal hip replacements and cancer. According to The Telegraph, next month researchers from the University of Bristol will present their findings at the British Hip Society conference. Researchers participating in the stu...

The high hip replacement failure rate of DePuy’s recalled ASR metal-on-metal hip implants has raised new concerns for British health authorities, who fear that patients who received the devices were never notified. Given the severe metal-on-metal hip implant problems reported by patients, in Janua...

Bernstein Liebhard LLP reports on a February 22, 2012 article published in the New York Times revealing that a Johnson & Johnson (“J&J”) executive notified senior management that the Food and Drug Administration (“FDA”) refused to approve one version of the now-recalled DePuy ASR hip...

As part of its continuing coverage of the fallout stemming from the August 2010 worldwide DePuy ASR hip recall, on February 22, 2012, the New York Times reported that top executives at Johnson & Johnson (“J&J”) had early knowledge of ASR hip replacement problems associated with its ASR h...

Bernstein Liebhard LLP reports on a February 15, 2012 article published in the New York Times revealing that Johnson & Johnson (“J&J”) continued to sell one model of its DePuy ASR hip replacement implants abroad after the U.S. Food and Drug Administration (“FDA”) rejected J&J’s...

On February 8, 2012, research presented at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (“AAOS”) concluded that patients who suffer a Fosamax thigh fracture while taking bisphosphonates such as Fosamax, Boniva, Reclast and Actonel can decrease their risk of suffering f...

Bernstein Liebhard LLP is pleased to announce the launch of a new video that provides useful information for individuals who were affected by the DePuy ASR hip recall. The video can be found on the Firm’s website, as well as on YouTube. In August 2010, DePuy Orthopaedics, a subsidiary of Johnson &...